TCS 3,604.45 -47.20 (-1.29%) HDFCBANK 1,828.50 +3.25 (0.18%) 
HINDUNILVR 2,259.35 +22.60 (1.01%) INFY 1,570.40 -33.15 (-2.07%) HDFC 2,729.95 -17.05 (-0.62%) BHARTIARTL 1,730.95 +7.60 (0.44%) KOTAKBANK 2,171.30 +40.15 (1.88%) ICICIBANK 1,348.40 +11.65 (0.87%) ITC 409.80 +0.40 (0.10%) BAJFINANCE 8,948.75 -37.25 (-0.41%) MARUTI 11,521.45 -200.20 (-1.71%) HCLTECH 1,590.95 -35.85 (-2.20%) SBIN 771.60 -0.80 (-0.10%) NESTLEIND 2,251.05 +10.90 (0.49%) ASIANPAINT 2,337.70 -0.50 (-0.02%) WIPRO 262.10 -9.95 (-3.66%) DMART 4,078.15 +13.30 (0.33%) AXISBANK 1,101.90 +3.40 (0.31%) LT 3,491.00 -12.30 (-0.35%) HDFCLIFE 685.55 +3.40 (0.50%) SUNPHARMA 1,735.45 +4.25 (0.25%) ULTRACEMCO 11,504.50 -84.00 (-0.72%) ONGC 246.40 +4.20 (1.73%) BAJAJFINSV 2,005.95 +0.55 (0.03%) BPCL 278.45 +2.50 (0.91%) POWERGRID 290.45 -4.45 (-1.51%) TITAN 3,063.80 -21.85 (-0.71%) BRITANNIA 4,936.90 +98.75 (2.04%) NTPC 357.65 -3.15 (-0.87%) Download Unicorn Signals App
By EquityPandit
Zydus Cadila, has received final approval from US health regulator to market Dexmedetomidine Hydrochloride injection.
The company in a regulatory filing stated that, the approval is to market Dexmedetomidine Hydrochloride injection 200 mcg (base)/2 ML and 100 mcg (base)/ ML single dose virals. It is used for sedation of intubated and mechanically ventilated patients.
Furthermore, the injection will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahemdabad.
